Melody L. Stallings-Mann

Dr. Melody L. Stallings-Mann


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MSMelody L. Stallings-Mann
Melody L. Stallings-Mann
JWJens Waldmann
Jens Waldmann
YZYing Zhang
Ying Zhang
EMErin Miller
Erin Miller
MGMona L. Gauthier
Mona L. Gauthier
DRDerek Radisky
Derek Radisky
Rac1b mediates the matrix metalloproteinase–induced epithelial-mesenchymal transition in lung adenocarcinoma and is a potential therapeutic target in early-stage lung cancer.

2 September 2019 in BMC Genomics
Verified
Journal Article
Open access
PDF file
ABAditya Bhagwate
Aditya Bhagwate
YLYuanhang Liu
Yuanhang Liu
SWStacey J. Winham
Stacey J. Winham
SMSamantha J. McDonough
Samantha J. McDonough
MSMelody L. Stallings-Mann
Melody L. Stallings-Mann
CWChen Wang
Chen Wang
Archived formalin fixed paraffin embedded (FFPE) samples are valuable clinical resources to examine clinically relevant morphology features and also to study genetic changes. However, DNA quality and quantity of FFPE samples are often sub-optimal, and resulting NGS-based genetics variant detections are prone to false positives. Evaluations of wet-lab and bioinformatics approaches are needed to optimize variant detection from FFPE samples. As a pilot study, we designed within-subject triplicate samples of DNA derived from paired FFPE and fresh frozen breast tissues to highlight FFPE-specific artifacts. For FFPE samples, we tested two FFPE DNA extraction methods to determine impact of wet-lab procedures on variant calling: QIAGEN QIAamp DNA Mini Kit (“QA”), and QIAGEN GeneRead DNA FFPE Kit (“QGR”). We also used negative-control (NA12891) and positive control samples (Horizon Discovery Reference Standard FFPE). All DNA sample libraries were prepared for NGS according to the QIAseq Human Breast Cancer Targeted DNA Panel protocol and sequenced on the HiSeq 4000. Variant calling and filtering were performed using QIAGEN Gene Globe Data Portal. Detailed variant concordance comparisons and mutational signature analysis were performed to investigate effects of FFPE samples compared to paired fresh frozen samples, along with different DNA extraction methods. In this study, we found that five times or more variants were called with FFPE samples, compared to their paired fresh-frozen tissue samples even after applying molecular barcoding error-correction and default bioinformatics filtering recommended by the vendor. We also found that QGR as an optimized FFPE-DNA extraction approach leads to much fewer discordant variants between paired fresh frozen and FFPE samples. Approximately 92% of the uniquely called FFPE variants were of low allelic frequency range (< 5%), and collectively shared a “C > T|G > A” mutational signature known to be representative of FFPE artifacts resulting from cytosine deamination. Based on control samples and FFPE-frozen replicates, we derived an effective filtering strategy with associated empirical false-discovery estimates. Through this study, we demonstrated feasibility of calling and filtering genetic variants from FFPE tissue samples using a combined strategy with molecular barcodes, optimized DNA extraction, and bioinformatics methods incorporating genomics context such as mutational signature and variant allelic frequency.

3 August 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JFJonine D. Figueroa
Jonine D. Figueroa
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
LBLouise A. Brinton
Louise A. Brinton
MPMaya M. Palakal
Maya M. Palakal
ADAmy C. Degnim
Amy C. Degnim
MSMark E. Sherman
Mark E. Sherman

13 January 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
SASabina Adhikary
Sabina Adhikary
THTanya L. Hoskin
Tanya L. Hoskin
MSMelody L. Stallings-Mann
Melody L. Stallings-Mann
MAMuhammad Arshad
Muhammad Arshad
MFMarlene H. Frost
Marlene H. Frost
ADAmy C. Degnim
Amy C. Degnim
Purpose: We quantified cytotoxic T cells in nonmalignant breast tissues from women with and without subsequent breast cancer to assess evidence of whether immunosurveillance may be suppressed prior to tumor development.Methods: We used an age-matched set of breast tissues from women with benign breast disease (BBD) who subsequently developed breast cancer (BBD with later BC), women with BBD who remained cancer free (BBD cancer-free), and normal Komen Tissue Bank (KTB) tissue donors (KTB controls). We evaluated terminal duct lobular units (lobules) for degree of epithelial abnormality and density of dual-positive CD8/CD103 T cells, as CD103+ cells are thought to be a subset of CD8+ cytotoxic T cells located primarily in the intraepithelial compartment.Results: In 10 sets of age-matched women, 256 breast lobules were studied: 85 in BBD women with later BC, 85 in BBD cancer-free women, and 86 in KTB donors. The majority of all lobules were histologically normal (N = 143, 56%), with 65 (25%) nonproliferative fibrocystic change, and 48 (19%) proliferative epithelial change (with or without atypia). In BBD women with later BC, median CD8+/CD103+ cell density was 39.6, 31.7, and 10.5 cells/mm2(p = 0.002) for normal, nonproliferative, and proliferative lobules. In BBD cancer-free women, median CD8+/CD103+ cell density values were 46.7, 14.3, and 0 cells/mm2(p = 0.004) respectively. In KTB donors, CD8+/CD103+ cell density was not significantly different across the lobule types (medians 0, 5.8, 10.7,p = 0.43).Conclusion: In women with BBD, breast lobules with increasing epithelial abnormality show significant decreases in cytotoxic T cells as measured by CD8/CD103 staining, suggesting that impaired immunosurveillance may be a component of the earliest stages of breast cancer development.

2 May 2026 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
NCNicole Cruz-Reyes
Nicole Cruz-Reyes
HLHongling Liang
Hongling Liang
MSMelody L. Stallings-Mann
Melody L. Stallings-Mann
LPLaura Maria Pacheco-Spann
Laura Maria Pacheco-Spann
BMBryan M. McCauley
Bryan M. McCauley
DRDerek Radisky
Derek Radisky
Benign breast disease (BBD) is common and confers heterogeneous increases in breast cancer risk; however, risk prediction relies mainly on histopathology a

27 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MSMark Sherman
Mark Sherman
JCJodi C. Carter
Jodi C. Carter
RVRobert A Vierkant
Robert A Vierkant
MSMelody L. Stallings-Mann
Melody L. Stallings-Mann
LPLaura Maria Pacheco-Spann
Laura Maria Pacheco-Spann
DRDerek Radisky
Derek Radisky
Background: Discovering risk biomarkers in small benign breast disease (BBD) biopsies is constrained by scarce tissue and microanatomic heterogeneity of terminal duct lobular units (TDLUs). We tested whether tissue-sparing tissue microarray (TMA)–based Digital Spatial Profiling (DSP) can deliver reproducible, biologically coherent protein measurements across benign lobules and breast cancers (BCs), and how well DSP aligns with standard immunoassays. Methods: We performed a pilot using tissues from the Mayo Clinic BBD cohort using TMAs representing four contexts: terminal duct lobular units (TDLUs) from BBD biopsies preceding BC and matched BBD-controls, subsequent BCs, and BC-associated TDLUs. We profiled 79 proteins by DSP (37 retained after QC) and benchmarked against chromogenic IHC and OPAL immunofluorescence. Reproducibility was evaluated using intraclass correlation coefficients (ICCs), cross-platform agreement (weighted kappa), marker correlations, and mixed-effects models with false-discovery-rate (FDR) control. Results: We analyzed 368 BBD-TDLU cores (88 cases; 88 controls), 204 BC cores and 110 BC-associated TDLU cores. ICCs were highest in BC tissues, and lower in BC-associated TDLUs and BBD-TDLUs. Agreement was slight–to-fair in TDLUs but moderate (ER/PR) to substantial (BCL2) in BC. DSP recapitulated expected immunologic correlations (CD45 with T-cell, B-cell, and macrophage markers) and tissue-type gradients (BC > BC-associated TDLUs > BBD-TDLUs). Exploratory case–control differences in BBD-TDLUs did not persist after FDR control. Conclusions: TMA-based DSP is feasible in archival breast tissues and yields biologically coherent, cross-platform-benchmarked profiles that are particularly robust in BC, while conserving scarce TDLUS and clarifying current limits of single-marker risk stratification from benign lobules. These data provide a foundation for refined sampling and expanded panels in future TDLU-focused studies.